[A double-blind study of alizapride in nausea and emesis induced by cancer chemotherapeutic agents (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007540:Isonipecotic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D010640:Phenothiazines / Q000627:therapeutic use*; D010919:Placebos; D011759:Pyrrolidines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D007540:Isonipecotic Acids; D010640:Phenothiazines; D010919:Placebos; D011759:Pyrrolidines; C005260:metopimazine; C033968:alizapride
Etude en double insu d'un nouvel anti-émétique, l'alizapride, dans les nausées et vomissements de la chimiothérapie anti-cancéreuse.